10x Genomics is having its best month in years — up 38% in July alone — and the shorts are running for the exits.
The most striking development this week is the speed of the short-interest unwind. Short interest has fallen 33% over the past month, from roughly 21.5 million shares to 14.3 million, now sitting at 12.3% of free float. That remains a genuinely elevated level for a life-sciences tools name, but the direction is unambiguous. Most of the covering happened in a concentrated window: from early July, when shorts held more than 22 million shares, the position has been cut by almost a third in five weeks. The stock's 14% jump on Friday — following Q2 results reported after the close on Thursday — has accelerated that retreat. Borrow conditions paint a relaxed picture alongside the covering: cost to borrow has eased 17% this week to 0.43%, barely above risk-free, and borrow availability has ballooned to 712% — meaning the lending pool holds roughly seven shares for every one currently shorted. There is no squeeze mechanism at work here. Shorts are simply choosing to leave.
Options sentiment aligns with the bullish price action rather than challenging it. The put/call ratio dropped to 0.31 on Friday, 1.5 standard deviations below its 20-day average of 0.34. By the standards of this name, that's near the call-heavy end of the range — the 52-week low on PCR is 0.06, so there's room to go further — but the clear message is that options buyers are leaning into upside rather than hedging. The short score has also been moving in the right direction, falling from 60 in late July to 55.6 as of Thursday, consistent with a stock where short-side pressure is abating rather than building.
The Street's response to the earnings print has been swift but measured in its language. Morgan Stanley raised its target from $37 to $40 on Friday while holding its Equal-Weight rating — a classic "acknowledge the move, don't chase it" posture. Citigroup lifted its target to $50 from $45, also retaining Neutral. Both firms are still below the current price of $52.15, a notable divergence: the consensus mean target sits at $46.31, implying the stock has already traded through the average analyst's fair-value estimate. Canaccord Genuity is the lone outlier with a Buy rating and a $50 target, while Barclays Overweight has a $40 target last set in June. The broad analyst posture is cautiously constructive — targets are moving up sharply (Leerink lifted from $23 to $40 in mid-July, Canaccord from $32 to $50) but the absence of upgrades from Neutral to Buy is a tell. Bears point to the structural challenge: 2024 revenues were under pressure from double-digit pricing headwinds and volumes that were flat at best, with a meaningful recovery not expected until 2027. Bulls counter that Chromium consumables volumes are recovering and the 2027 platform ramp could be significant. Valuation complicates the picture — price-to-book has risen to 7.1x following the rally, EV/EBITDA is deeply negative given ongoing losses, and the PE at 371x reflects a company still far from normalised earnings.
Institutional ownership adds an interesting layer. FMR (Fidelity) is the largest holder at 14.7% of shares, having added 5.8 million shares as recently as the end of June — a substantial accumulation that preceded much of the rally. ARK Investment holds 9.2% but trimmed slightly through July. On the insider side, the picture is less encouraging: CEO Serge Saxonov sold roughly 30,000 shares across four transactions in late June at prices ranging from $33 to $36, and the CFO sold in May at $24. Net insider sales over 90 days total approximately 101,000 shares. These are modest in scale relative to the float, and the May/June sales came well below current prices, so the signal is limited — but the direction is worth noting against the backdrop of a 38% monthly rally.
The next scheduled earnings event is 4 November. Between now and then, the key question for TXG is whether the post-print enthusiasm can be sustained when the Street's consensus target sits below Friday's close — and whether the remaining 12% short interest, concentrated in a still-loss-making name, continues to dissolve or finds a reason to rebuild.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
